Omega-transaminase as well as mutant, vector, engineering bacterium and application thereof

By genetically modifying ω-transaminase and constructing mutants, the problems of low optical purity and yield in existing technologies have been solved, enabling the industrial application of highly efficient bioenzymatic synthesis of (R)-N-Boc-3-aminopiperidine.

CN118995657APending Publication Date: 2024-11-22SOUTHWEST UNIV

Patent Information

Application Number
CN202411176262.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing chemical synthesis and chiral resolution methods for preparing optically pure (R)-3-aminopiperidine suffer from low yield, difficulty in controlling optical purity, and high cost. Furthermore, the conversion efficiency of natural ω-transaminase is insufficient to meet industrial requirements.

Method used

By genetically modifying ω-transaminase derived from Penicillium chrysogenum to construct mutants and optimize their catalytic performance, (R)-N-Boc-3-aminopiperidine was synthesized using recombinant genetically engineered bacteria via a bio-enzymatic method under specific reaction conditions.

Benefits of technology

High conversion rate and high optical purity of (R)-N-Boc-3-aminopiperidine were achieved. The catalytic activity of the mutant was increased by 4.51 times, the optical purity of the product reached more than 99%, and the conversion rate reached 18.26%.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995657A_ABST
    Figure CN118995657A_ABST
Patent Text Reader

Abstract

The invention discloses an omega-transaminase mutant and an application of the omega-transaminase mutant in synthesis of (R)-N-Boc-3-aminopiperidine.The codon of a transaminase coding gene is optimized, and the transaminase coding gene with the nucleotide sequence shown as SEQ ID NO.1 is obtained. On the basis, a series of transaminase mutants are obtained by constructing a mutant library of transaminase, and the optimal mutant is screened out. The obtained recombinant transaminase catalyst can catalytically synthesize (R)-N-Boc-3-aminopiperidine, the reaction conversion rate can reach 18.26%, and the optical purity of the product can reach 99% or above. The activity of the transaminase mutant obtained through protein engineering modification is obviously improved compared with that of a wild type female parent, the activity of the optimal mutant is improved by 4.51 times compared with that of the wild type female parent, and the ee of the product is 99% or above.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biochemical engineering technology, in particular to an ω-aminotransferase and a mutant thereof, a carrier and an engineering bacterium, and also to application of the ω-aminotransferase mutant in synthesizing (R)-N-Boc-3-aminopiperidine. Background Art

[0002] Heterocyclic chiral amines are important components of chiral amine compounds and are common structural units in many bioactive natural products and drug-related compounds. In recent years, more than 50% of the unique small molecule drugs approved by the FDA contain nitrogen heterocycles, and piperidines among six-membered heterocyclic amines occupy an important position in heterocyclic amine drugs (Kohls H, et al. Currentopinion in chemical biology, 2014, 19: 180-192; Paul CE, et al. Organic Process Research & Development, 2014, 18 (6): 788-792). Among them, optically pure (R)-3-aminopiperidine has been used in the synthesis of a variety of new drugs for the treatment of type 2 diabetes (T2DM), including linagliptin, alogliptin benzoate and trelagliptin succinate, etc., and other dipeptidyl peptidase-IV inhibitor drugs (Xu Liangkui, et al. Central South Pharmacy, 2008, 6 (1): 85-88). The synthesis of (R)-N-3-aminopiperidine is mainly through chemical synthesis, kinetic resolution, and the emerging enzyme catalytic synthesis (Ward J, et al. Current organic chemistry, 2010, 14 (17): 1914–1927). There are two main chemical synthesis methods: chemical asymmetric reduction of prochiral ketones and synthesis using chiral compounds as raw materials. The method of chemical asymmetric synthesis using prochiral ketones is the most traditional, and its product yield and optical purity are difficult to control, and it is extremely difficult to synthesize some complex structure compounds (Yi SS, et al. Process Biochemistry, 2007, 42 (5): 895–898). Using compounds containing chiral centers as raw materials not only does not require asymmetric synthesis and kinetic resolution during the reaction, but also the optical purity of the product can be guaranteed. However, this method is easily limited by the cost of chiral raw materials, and the reaction steps are lengthy and the yield is not high. Compared with chemical synthesis, chiral separation is often simple and rapid, but different separation methods have significant defects. For example, the crystallization separation conditions are harsh and the yield is not high, while the separation using biological or chromatographic methods requires high costs.

[0003] So far, the application of chemical synthesis to prepare (R)-3-aminopiperidine is innumerable. However, the methods of chemical synthesis and chiral resolution still have many shortcomings in application, such as yield, optical purity, and cost control. With the rise of biology and the need for green production, the preparation of chiral 3-aminopiperidine by biotransformation has attracted people's attention in recent years (Xie Y, et al. Catalysis science & technology, 2022, (7): 2162–2175). The biotransformation method uses chiral ketone 3-piperidone or 3-piperidone with an N-protecting group as raw material to synthesize (R)-3-aminopiperidine by asymmetric catalysis of (R)-type transaminase. For example, Fan Wenchao et al. used recombinant D-aminotransferase, and Yang Sheng et al. and Robins et al. used ω-aminotransferase to biotransform 3-piperidone to prepare (R)-3-aminopiperidine (CN104178536; CN103865964; CortiM, et al. Journal of Pharmaceutical & Biomedical Analysis, 2019, 169: 260–268). In their studies, natural aminotransferases were used, but the conversion efficiency was not high and could not be applied to large-scale industrial production.

[0004] The biosynthesis of (R)-3-aminopiperidine using ω-aminotransferase has a broad application prospect. The molecular modification of natural ω-aminotransferase using semi-rational design to improve its catalytic performance is of great significance to promote the industrial application of biosynthesis of (R)-3-aminopiperidine. Summary of the invention

[0005] In view of this, one of the objects of the present invention is to provide an ω-aminase; a second object of the present invention is to provide a gene encoding the ω-aminase; a third object of the present invention is to provide an ω-aminase mutant; a fourth object of the present invention is to provide a vector containing the gene encoding the ω-aminase mutant; a fifth object of the present invention is to provide a recombinant genetically engineered bacterium containing the vector; a sixth object of the present invention is to provide the use of the ω-aminase mutant in the bioenzymatic preparation of (R)-N-Boc-3-aminopiperidine.

[0006] In order to achieve the above object, the present invention provides the following technical solutions:

[0007] 1. An ω-aminotransferase from Penicillium chrysogenum, wherein the amino acid sequence of the ω-aminotransferase is shown in SEQ ID NO.2.

[0008] 2. A gene encoding the ω-aminotransferase, the nucleotide sequence of which is shown in SEQ ID NO.1.

[0009] 3. A ω-aminase mutant, the amino acid sequence of which is obtained by mutation of the ω-aminase shown in SEQ ID NO.2, wherein the mutation is any one of V60S, E115Y, E115Q, T272S, T272G, T273S, T273K, T273A, V60S / E115Y / T273S, E115Y / T272S / T273A, V60S / E115Q / T273S, V60S / E115Y / T272S / T273S, V60S / E115Y / T272S / T273A or V60S / E115Q / T272S / T273K.

[0010] Preferably, the amino acid sequence of the ω-aminotransferase mutant encoding the mutation V60S / E115Y / T272S / T273S is shown in SEQ ID NO.4.

[0011] Preferably, the present invention provides a gene encoding the ω-aminotransferase mutant, wherein the nucleotide sequence of the gene is shown in SEQ ID NO.3.

[0012] 4. A vector containing the gene encoding the ω-aminotransferase mutant.

[0013] 5. A recombinant genetically engineered bacterium containing the vector.

[0014] 6. Application of the ω-aminotransferase mutant in the preparation of (R)-N-Boc-3-aminopiperidine by bioenzymatic method.

[0015] Preferably, the application of the present invention comprises the following steps: fermenting and culturing an engineered bacterium containing a gene vector encoding a ω-aminotransferase mutant, purifying to obtain a recombinant ω-aminotransferase, using the recombinant ω-aminotransferase as a biocatalyst, N-Boc-3-piperidone as a substrate, α-phenylethylamine as a co-substrate, 5-pyridoxal phosphate as a coenzyme, and a pH 8.0 buffer as a reaction medium to form a reaction system, reacting at 30° C., and separating and purifying the reaction solution after the reaction is complete to obtain (R)-N-Boc-3-aminopiperidine.

[0016] Preferably, the concentration of the recombinant ω-aminotransferase is 1.0 mg / mL, the concentration of N-Boc-3-piperidone is 5 mM, the concentration of α-phenylethylamine is 10 mM, 50 mM Tris-HCl at pH 7.5.0 to 9.0 is used as the reaction medium, and the reaction time is 60 min.

[0017] The beneficial effects of the present invention are as follows: the present invention discloses a ω-transaminase mutant and its application in the synthesis of (R)-N-Boc-3-aminopiperidine. The present invention optimizes the codons of the transaminase encoding gene to obtain a transaminase encoding gene with a nucleotide sequence as shown in SEQ ID NO.1. On this basis, a series of transaminase mutants are obtained by constructing a mutant library of transaminase, and the optimal mutant is screened out. The recombinant transaminase catalyst obtained by the present invention can catalyze the synthesis of (R)-N-Boc-3-aminopiperidine, the reaction conversion rate can reach 18.26%, and the product optical purity can reach more than 99%. Moreover, the transaminase mutant obtained by protein engineering has significantly improved activity compared with the wild-type parent, the optimal mutant has an activity increase of 4.51 times compared with the wild-type parent, the reaction conversion rate can reach 86.65%, and the product ee is more than 99%. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the present invention provides the following drawings for illustration:

[0019] Figure 1 This is the recombinant plasmid map of ω-aminotransferase.

[0020] Figure 2 The electrophoresis diagrams of the expression and purification of ω-aminotransferase and mutant proteins are shown in Figures 1-6 and 7-12, respectively. The purification process of mutant proteins is shown in Figures 1-6 and 7-12, respectively. The purification process of wild-type proteins is shown in Figures 7-12. M: low molecular weight protein marker; 1: mutant protein fermentation supernatant; 2: mutant protein cell crushing supernatant; 3: mutant protein cell crushing precipitation supernatant; 4: mutant protein affinity chromatography 20mM imidazole buffer eluted protein; 5: mutant protein affinity chromatography 300mM imidazole buffer eluted protein; 6: mutant concentrated protein; 7: fermentation supernatant (WT); 8: cell crushing supernatant (WT); 9: cell crushing precipitation supernatant (WT); 10: affinity chromatography 20mM imidazole buffer eluted protein (WT); 11: affinity chromatography 300mM imidazole buffer eluted protein (WT); 12: concentrated protein (WT).

[0021] Figure 3 This is the optimal reaction temperature diagram of ω-aminotransferase.

[0022] Figure 4 This is the optimal pH diagram for ω-aminotransferase.

[0023] Figure 5 This is the time rate curve of ω-aminotransferase.

[0024] Figure 6 The effect of ω-aminotransferase substrate concentration on enzyme activity.

[0025] Figure 7Chiral NMR of PCTA conversion product 1 H spectrum and 13 C spectrum.

[0026] Figure 8 Chiral NMR of the transformation product of pcta mutant 1 H spectrum and 13 C spectrum.

[0027] Fig. 9 This is the chiral HPLC spectrum of the pcta conversion product.

[0028] Fig.10 This is the chiral HPLC spectrum of the pcTA-1 transformation product. DETAILED DESCRIPTION

[0029] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0030] Example 1. Transformation of ω-aminotransferase encoding gene and construction of prokaryotic expression vector

[0031] The ω-aminotransferase (PCTA for short) described in the present invention is an ω-aminotransferase (Gene ID: 211591081) derived from Penicillium chrysogenum, and its amino acid sequence is shown in SEQ ID No. 2. Codon optimization is performed using Escherichia coli as a host, and the nucleotide sequence obtained after optimization is shown in SEQ ID NO. 1. A His-tag is added to the end of the nucleotide sequence to facilitate subsequent protein purification. In addition, BamH I and XhoI restriction sites are designed at both ends of the above gene sequence, and plasmid pET-32a is selected as an expression vector, which is submitted to a commercial company to construct an expression vector. An expression vector containing a wild-type ω-aminotransferase recombinant gene is obtained, named pET32a-pcta ( Figure 1 ).

[0032] Example 2. Establishment of ω-transaminase point mutant library and saturation mutation library

[0033] We used Swiss-model and Aspergillus terreus aminotransferase as template (PDB ID: 4CE5) to construct a homology model of the ω-aminotransferase encoding gene described in Example 1. Discovery Studio was used for protein and small molecule activity docking. Through the method of virtual amino acid mutation prediction, combined with the structural characteristics of the active center of ω-aminotransferase and the unique catalytic reaction mechanism, 7 site-directed mutation types were analyzed and determined, namely E115Y, K178R, T273K, F113K, V60A, W182R, G214R, and 4 saturation mutation sites, namely V60Satur, E115Satur, T272Satur, and T273Satur. Using the expression vector pET32a-pcta constructed in Example 1 as a template, the point mutation primers (Table 1) and degenerate primers (Table 2) of the mutant amino acid sites were designed using the "Oligo 7" software. The codons are required to be as consistent as possible with the codon preference of E. coli, the upstream and downstream of the mutation site contain at least 7bp bases, and the forward and reverse primer dimer temperature is 10°C lower than the annealing temperature.

[0034] Table 1 Site-directed mutagenesis primer design table

[0035]

[0036] Table 2 Saturation mutation primer design table

[0037]

[0038] We used the RePure-A gene amplification instrument for whole plasmid amplification. Different PCR reaction systems were used for point mutation and saturation mutation.

[0039] The 10 μL point mutation PCR reaction system includes: 0.2 μL pET32a-pcta plasmid template; 0.4 μL forward primer; 0.4 μL reverse primer; 5 μL 2×T8 High fidelity master mix; 4 μL ddH2O.

[0040] The forward primer is a specific primer used in the construction process of different mutants, as shown in Table 1. Taking the construction of E115Y as an example, the forward primer in the amplification system is the sequence shown in SEQ ID NO.5. The reverse primer is a specific primer used in the construction process of different mutants, as shown in Table 1. Taking the construction of E115Y as an example, the reverse primer in the amplification system is the sequence shown in SEQ ID NO.6.

[0041] The 10μL saturation mutation PCR reaction system includes: 0.2μL pET32a-pcta plasmid template; 0.02μL F-TGG; 0.02μL F-ATG; 0.12μL F-VMA; 0.2μL F-NDT; 0.4μL R-NNS; 5μL 2×T8 High fidelity master mix; 4μL ddH2O.

[0042] The forward primers are specific primers used in the construction process of different mutants, as shown in Table 2. Taking the construction of 60Satur as an example, F-TGG in the amplification system is the sequence shown in SEQ ID NO.22; F-ATG is the sequence shown in SEQ ID NO.21; F-VMA is the sequence shown in SEQ ID NO.20; F-NDT is the sequence shown in SEQ ID NO.19. The reverse primers are specific primers used in the construction process of different mutants, as shown in Table 2. Taking the construction of 60Satur as an example, the reverse primer R-NNS in the amplification system is the sequence shown in SEQ ID NO.23.

[0043] The reaction conditions of PCR were as follows: (1) pre-denaturation at 98°C for 2 min; (2) denaturation at 98°C for 15 s; (3) T m (4) 72°C annealing for 30 s; (2) to (4) 72°C extension for 3 min; the above steps (2) to (4) were cycled 18 times, and finally 72°C final extension for 5 min.

[0044] The plasmid obtained by PCR amplification was digested with Dpn I enzyme and stored in a refrigerator at -20°C. The expression vector containing the mutation site was named pET32a-pcta-m.

[0045] Case study 3. Construction of genetically engineered bacteria for ω-aminotransferase and its mutants and preparation of cell catalysts

[0046] The expression vector pET32a-pcta prepared in Example 1 and the expression vector pET32a-pcta-m prepared in Example 2 were transformed into competent cells E. coli BL21 (DE3) by heat shock method, amp resistance plates were coated, single colonies were selected for sequencing verification, and the correctly mutated strains were stored in a -80°C refrigerator. In this way, genetically engineered bacteria with Escherichia coli as the host were obtained. The genetically engineered bacteria containing the expression vectors pET32a-pcta and pET32a-pcta-m were named E. coli BL21 (DE3) pET32a-pcta and E. coli BL21 (DE3) pET32a-pcta-m, respectively.

[0047] The genetically engineered bacteria containing the coding sequence of transaminase and its mutants were inoculated into LB liquid medium containing amp resistance, placed in a 37°C shaker, 220 rpm and cultured overnight to obtain the primary seed. The primary seed was inoculated into 100 mL of LB liquid medium containing amp at a 1% (volume ratio) inoculation ratio, placed in a 37°C shaker, 220 rpm and cultured for 2-3 hours. When the OD of the culture solution reaches 600 When the concentration reaches about 0.6-0.8, add IPTG with a final concentration of 0.1-0.8mM to induce expression, and the induction temperature is 16-37° C. The preferred IPTG concentration is 0.4mM, and the preferred induction temperature is 16° C. Under the preferred conditions, culture at 220rpm for 20h, collect the cells by centrifugation, and obtain the cell catalyst of transaminase.

[0048] Example 4. Protein purification of ω-aminotransferase and its mutants

[0049] Take the wet bacteria obtained in Implementation Case 3, add 8mL 50mM Tris-HCl (10mM imidazole), and resuspend the bacteria. Use a cell ultrasonic disruptor to disrupt the bacteria, and set the disruption program: power 200W, ultrasound 3s, interval 8s, and continue for 15min. Disrupt until the bacterial solution becomes clear and transparent. After the disruption is completed, centrifuge at 4°C, 12000rpm for 10min to obtain the bacterial supernatant. At the same time, keep a sample of the supernatant of the broken bacteria and a sample of the broken sediment of the broken bacteria.

[0050] use Protein purification was performed using the GO protein chromatography system.

[0051] System cleaning: Connect the HisTrap HP 1mL pre-packed chromatography column and use filtered pure water at a flow rate of 1mL / min to clean for 15min to remove soluble impurities and protective solution ethanol.

[0052] Column balance: 50 mM Tris-HCl (20 mM imidazole) as mobile phase A, flow rate 1 mL / min balance until UV absorption, conductivity balance to zero line and no longer fluctuate.

[0053] Affinity chromatography: Select the Affinity method, use a sample loop, and inject 2 mL of the supernatant from the broken bacteria; flow into 3 mL of 50 mM Tris-HCl (20 mM imidazole) to obtain impurity proteins, and keep the impurity protein sample. Flow into 3 mL of 50 mM Tris-HCl (300 mM imidazole), and obtain affinity-purified proteins based on the protein peak. Keep the affinity-purified protein sample.

[0054] Protein desalting: Connect the HisTrap Desalting pre-packed chromatography column, and follow the same system cleaning and column balancing steps as above. Select the Desalting method, use the injection loop, inject 2 mL of affinity purified protein solution, flow into 15 mL of 20 mM Tris-HCl, and obtain the desalted protein based on the protein peak. Keep the desalted protein sample.

[0055] Ultrafiltration concentration: Take an ultrafiltration concentration centrifuge tube (molecular weight cutoff 10kDa), add 4mL ddH2O, centrifuge at 4℃, 6000rpm for 10min to remove ethanol; add 4mL 20mM Tris-HCl (pH 8.0) for balance, centrifuge at 4℃, 6000rpm for 10min; add 4mL desalted protein, centrifuge at 4℃, 6000rpm to concentrate to 250μL. Save the concentrated protein sample, add 50% volume sterile glycerol, and store at -80℃.

[0056] The purity of the target protein was determined by SDS-PAGE. The results are shown in the attached manual. Figure 2 shown.

[0057] according to Figure 2 The results show that: under 20mM imidazole solution, impurities are washed away, and only a small amount of target protein is eluted, indicating that the artificially added His tag can bind well to the nickel column, and the target protein can be separated and purified by affinity chromatography. Under 300mM imidazole solution, the target protein can be eluted, and the final protein band is single and has high purity. Therefore, high-purity PCTA can be obtained through His tag design and nickel column affinity chromatography.

[0058] Example 5. Determination of the activity of ω-transaminase and its mutants

[0059] The pure enzyme stored in a -80°C refrigerator as described in Example 4 was taken and dissolved on ice. The protein concentration of the pure enzyme solution was determined by the BCA (Bicinchoninic Acid) method and diluted with 20 mM Tris-HCl to a final concentration of 1 mg / mL.

[0060] Activity detection principle: The acetophenone method is a simple and efficient method for detecting the activity of ω-aminotransferase. Using α-phenylethylamine as the amino donor, the byproduct acetophenone has a maximum absorption peak at 245nm, while α-phenylethylamine and the substrate sodium pyruvate have no obvious absorption at this wavelength. The amount of acetophenone generated can be calculated by detecting the change in the absorbance value at a wavelength of 245nm, thereby calculating the enzyme activity of ω-aminotransferase. The enzyme activity unit (U) is the amount of enzyme required to produce 1μmol of product within 1min under the optimal reaction conditions. The specific activity of an enzyme refers to the number of activity units contained in a unit mass (usually per mg) of enzyme.

[0061] Enzyme activity detection method: The optimal reaction conditions were used for detection, i.e., 1.0 mg / mL enzyme solution as the basis, 50 mM Tris-HCl (pH 8.0) as the buffer, 10 mM amino donor substrate α-phenylethylamine, 5 mM amino acceptor substrate N-Boc-3-piperidone, and 30°C for 60 min. 10% volume of 1 mol / L dilute hydrochloric acid was added to the reaction system to terminate the reaction, and the reaction was centrifuged at 12000 rpm. The supernatant was diluted 10 times and a 96-well UV detection ELISA plate (Solarbio ) detect the change of absorbance value at 245nm wavelength.

[0062] Substrate N-Boc-3-piperidone conversion rate detection method: Shimadzu high performance liquid chromatograph SDP-M20A was used, and the detection column was WondaSil C18 Superb (5μm, 4.6mm×250mm). The mobile phase was 60% 0.1% trifluoroacetic acid aqueous solution and 40% acetonitrile isocratic elution. The column oven was 30°C, the flow rate was 0.5mL / min, the detection wavelength was 200nm, and the injection volume was 20μL. The substrate conversion rate was calculated using the external standard method.

[0063] HPLC external standard curve: accurately weigh 0.0199 g of N-Boc-3-piperidone and dissolve it in 50% acetonitrile-water solution, and dilute it to a 10 mL volumetric flask to prepare a mother solution with a concentration of 10 mM. Dilute it in sequence to prepare N-Boc-3-piperidone solutions with concentrations of 10, 8, 6, 4, 2, and 1 mM as HPLC external standard curve samples.

[0064] Preparation of test samples: After the reaction is completed, add 10% volume of 1 mol / L dilute hydrochloric acid to the reaction system to terminate the reaction, centrifuge at 12000 rpm for 10 min, add an equal volume of acetonitrile to the supernatant and mix thoroughly, centrifuge at 12000 rpm for 10 min again, filter the supernatant through a 0.22 μm microporous nylon filter membrane, and use it as a reaction conversion rate test sample.

[0065] After testing, as shown in Table 3, among the 7 point mutants, the conversion rate of mutant E115Y increased by 291.45% relative to the wild-type PCTA, and T273K increased by 78.66%, while the remaining 5 point mutants did not significantly improve, among which the activities of V60A, K178R, F113K, and W182R mutants decreased, especially the activity of mutant K178R was completely lost. Through the saturation mutation library screening, 6 new positive mutants V60S, E115Q, T272S, T272G, T273S, and T273A were obtained, and their relative activities are shown in Table 4.

[0066] Table 3 Activity of pcta and its point mutants

[0067] strain Conversion rate / % Relative activity / % pcta 18.26 100 V60A 5.45 29.84 F113K 10.27 56.27 E115Y 71.48 391.45 K178R 0 0 W182R 19.75 108.62 G214R 16.83 92.19 T273K 32.53 178.66

[0068] Table 4 Activities of forward mutants in the saturation mutant library

[0069] strain Relative activity / % pcta 100 V60S 183.54 E115Q 187.64 E115Y 364.96 T272S 180.20 T272G 208.85 T273A 194.53 T273S 176.84

[0070] Case study 6. Construction of ω-aminotransferase combination mutants and activity detection

[0071] The forward mutants E115Y, T273K, V60S, E115Q, T272S, T272G, T273S, and T273A were combined with double mutation, triple mutation, and quadruple mutation, and virtual amino acid combination mutation prediction was performed. The six combinations with the smallest mutation energy were selected and renamed:

[0072] pcTA-1: V60S-E115Y-T272S-T273S;

[0073] pcTA-2: V60S-E115Q-T272S-T273K;

[0074] pcTA-3: V60S-E115Y-T272S-T273A;

[0075] pcTA-4:V60S-E115Y-T273S;

[0076] pcTA-5:V60S-E115Q-T273S;

[0077] pcTA-6:E115Y-T272S-T273A.

[0078] The plasmid, transformation and purification process of the combined mutants are the same as those shown in "Implementation Case 2", "Implementation Case 3" and "Implementation Case 4". The primer design of the combined mutants is shown in Table 5.

[0079] Table 5 Combination mutation primer design table

[0080]

[0081] The process of combined mutant activity detection is the same as that shown in "Implementation Case 5". The activity detection results show that the mutant pcTA-1 has the largest activity improvement, with a substrate conversion rate of 86.65%, which is 5.51 times that of pcTA. The second mutant pcTA-6 also has a substrate conversion rate of 71.44%, but the activity of pcTA-5 is reduced by 51%. The specific results are shown in Table 6. The amino acid sequence of the ω-transaminase mutant encoding the mutation mode of V60S / E115Y / T272S / T273S is shown in SEQ ID NO.4, and the nucleotide sequence is shown in SEQ ID NO.3.

[0082] Table 6 Activity of combined mutants

[0083] strain Conversion rate / % Relative activity / % pcta 15.72 100 pcTA-1 86.65 551.21 pcTA-2 23.98 152.55 pcTA-3 53.96 343.25 pcTA-4 40.78 259.41 pcTA-5 7.71 49.05 pcTA-6 71.44 454.45

[0084] Implementation Case 7. Test of Optimal Reaction Conditions of ω-Transaminase

[0085] Optimal reaction temperature test: Based on 1.0 mg / mL enzyme solution, the transaminase activity was tested at different temperatures (20, 25, 30, 35, 40, 45, 50°C). The enzyme activity was determined according to the method described in Example 5, with the highest enzyme activity as 100%, and the relative enzyme activity at other temperatures was calculated. After testing, the optimal reaction temperature was 30°C (see Figure 3 ), the relative enzyme activity outside the optimal reaction temperature range of 5°C is less than 80%.

[0086] Optimal reaction pH test: Based on 1.0 mg / mL enzyme solution, enzyme activity was measured in different types and buffers at different pH values ​​(specifically including disodium hydrogen phosphate-citric acid buffer at pH=6.0, pH=6.5, and pH=7.0; Tris-HCl buffer at pH=7.5, pH=8.0, and pH=8.5; disodium hydrogen phosphate-potassium dihydrogen phosphate buffer at pH=9.0, pH=9.5, and pH=10.0). The enzyme activity detection method was determined according to the method described in Example 5, and the highest enzyme activity was taken as 100%, and the relative enzyme activity at the remaining pH values ​​was calculated. After testing, the optimal reaction pH of PCTA is between 8.0 and 8.5 (see Figure 4 ), the highest activity was selected as pH 8.0, and the buffer type for this pH range was Tris-HCl.

[0087] Optimal reaction time test: Based on 1.0 mg / mL enzyme solution, the enzyme activity was measured at 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, and 90 minutes. The enzyme activity detection method was determined according to the method described in Example 5. The average speed of the reaction time interval was used as the reaction speed at a certain time point, and the reaction time rate curve was drawn to determine the end time of the reaction. After testing, the maximum reaction speed of pcta (1.0 mg / mL) was around 30 minutes, and the enzyme reaction tended to be stable around 60 minutes. The time for enzyme activity determination was selected to be 60 minutes (see Figure 5 ).

[0088] Optimal substrate concentration test: Based on 1.0 mg / mL enzyme solution, enzyme activity was measured at substrate concentrations of 30, 25, 20, 15, 10, 5, 2.5, and 1 mM. The enzyme activity detection method was determined according to the method described in Implementation Case 5, and the initial reaction rate was detected to check the inhibition of the pcTA-catalyzed reaction of α-phenylethylamine and N-Boc-3-piperidone. After testing, the substrate inhibition of the byproduct acetophenone was the most serious. When it was greater than 10 mM, the enzyme activity was significantly inhibited, which was the rate-limiting factor of the reaction system. Since the product is a 1:1 conversion, although the inhibitory concentration of the substrate N-Boc-3-piperidone is 15 mM, the maximum concentration should be selected to be lower than 10 mM. The α-phenylethylamine substrate inhibition is the weakest, and the enzyme activity is not significantly affected when it is higher than 20 mM (see for details). Figure 6 ). Finally, the optimal substrate concentrations were determined to be 10 mM for the amino donor substrate α-phenylethylamine and 5 mM for the amino acceptor substrate N-Boc-3-piperidone.

[0089] In summary, the optimal reaction conditions for PCTA are based on 1.0 mg / mL enzyme solution, 50 mM Tris-HCl (pH 8.0) as buffer, 10 mM amino donor substrate α-phenylethylamine, 5 mM amino acceptor substrate N-Boc-3-piperidone, and reaction at 30°C for 60 min.

[0090] Implementation Case 8. Chiral Detection and Product Identification

[0091] The optical purity detection method of the product N-Boc-3-aminopiperidine: Shimadzu high performance liquid chromatograph LC 20A is used, and the sample is dissolved in 50% methanol: 50% ethanol; chromatographic column (Daicel): CHIRALPAK AD-H (5μm, 4.6mm×150mm). Mobile phase A is n-hexane, mobile phase B is ethanol, and the mobile phase ratio is 97% n-hexane isocratic elution. Inject 10μL, column temperature 35℃, detection wavelength 210nm, flow rate 1mL / min. Enantiomeric excess is usually expressed as ee%. The enantiomeric excess of (R)-N-Boc-3-aminopiperidine to (S)-N-Boc-3-aminopiperidine is calculated by the formula:

[0092]

[0093] [R]: (R)-N-Boc-3-aminopiperidine peak area

[0094] [S]: (S)-N-Boc-3-aminopiperidine peak area

[0095] Product identification method: The reaction liquid of the pcta and mutant group with the highest conversion rate is used for product extraction. Centrifuge about 20 mL of the reaction liquid, add hydrochloric acid to the supernatant to adjust the pH to 3, transfer to a separatory funnel, add 20 mL of ethyl acetate to extract twice, and combine the organic phases. Add sodium hydroxide to adjust the pH to 13, transfer to a separatory funnel, add 10 mL of ethyl acetate to extract twice, and combine the organic phases. Add saturated sodium chloride solution to the combined ethyl acetate to extract water-soluble impurities, extract twice, and discard the aqueous phase. Add a slightly excess of anhydrous sodium sulfate to the ethyl acetate to dry it, transfer the ethyl acetate to 70°C vacuum rotary evaporation, and dry to obtain a light yellow oily product. Weigh about 4 mg of the product, dissolve it in deuterated chloroform solution, and detect the product hydrogen spectrum by nuclear magnetic resonance. 1 H and carbon spectrum 13 C. Identify whether the product is N-Boc-3-aminopiperidine by spectral analysis.

[0096] The structure of the product N-Boc-3-aminopiperidine was determined by NMR 1 H Spectrum and 13 C carbon spectrum identification, after spectrum analysis and combined with the database hydrogen spectrum carbon spectrum comparison, it was determined that the product was N-Boc-3-aminopiperidine. For specific NMR results, see Figure 7 and Figure 8 The chirality and optical purity of the product N-Boc-3-aminopiperidine were determined by chiral HPLC. By comparing the retention time with that of the reference substance, it was found that the chirality of the pcta product was (R) configuration, with an enantiomeric excess of 99.4% ee. The chirality of the product of pcTA-1 was also (R) configuration, with an enantiomeric excess of 99.9% ee. The above results indicate that pcta is a strictly (R) selective ω-aminotransferase, which is consistent with the results in the literature. The molecular modification of pcta did not cause a change or decrease in its chiral selectivity. For specific HPLC results, see Fig. 9 and Fig.10 .

[0097] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.

Claims

1. An ω-aminotransferase from Penicillium chrysogenum, characterized in that The amino acid sequence of the ω-aminotransferase is shown in SEQ ID NO.

2.

2. A gene encoding the ω-aminotransferase according to claim 1, characterized in that: The nucleotide sequence of the gene is shown in SEQ ID NO.

1.

3. A ω-transaminase mutant, characterized in that: The amino acid sequence of the ω-aminase mutant is obtained by mutation of the ω-aminase shown in SEQ ID NO.2, and the mutation is any one of V60S, E115Y, E115Q, T272S, T272G, T273S, T273K, T273A, V60S / E115Y / T273S, E115Y / T272S / T273A, V60S / E115Q / T273S, V60S / E115Y / T272S / T273S, V60S / E115Y / T272S / T273A or V60S / E115Q / T272S / T273K.

4. The ω-aminotransferase mutant according to claim 3, characterized in that: The amino acid sequence encoding the ω-aminotransferase mutant with mutations of V60S / E115Y / T272S / T273S is shown in SEQ ID NO.

4.

5. A gene encoding the ω-aminotransferase mutant according to claim 4, characterized in that: The nucleotide sequence of the gene is shown in SEQ ID NO.

3.

6. A vector containing a gene encoding the ω-aminotransferase mutant according to claim 3.

7. A recombinant genetically engineered bacterium containing the vector according to claim 6.

8. Use of the ω-aminotransferase mutant according to claim 3 in the preparation of (R)-N-Boc-3-aminopiperidine by a bioenzymatic method.

9. The use according to claim 8, characterized in that: The method comprises the following steps: fermenting and culturing an engineering bacterium containing a gene vector encoding an ω-aminotransferase mutant, purifying to obtain a recombinant ω-aminotransferase, using the recombinant ω-aminotransferase as a biocatalyst, N-Boc-3-piperidone as a substrate, α-phenylethylamine as a co-substrate, 5-pyridoxal phosphate as a coenzyme, and a buffer solution of pH 8.0 as a reaction medium to form a reaction system, reacting at 30° C., and separating and purifying the reaction solution after the reaction is complete to obtain (R)-N-Boc-3-aminopiperidine.

10. The use according to claim 9, characterized in that: The concentration of the recombinant ω-aminotransferase is 1.0 mg / mL, the concentration of N-Boc-3-piperidone is 5 mM, the concentration of α-phenylethylamine is 10 mM, 50 mM Tris-HCl with a pH of 7.5.0 to 9.0 is used as the reaction medium, and the reaction time is 60 min.

Citation Information

Patent Citations

  • Method for synthesizing (R)-3-amino-piperidine by adopting transaminase method

    CN103865964A

Cited By

  • Transaminase mutant applied to synthesis of N-Boc-3-aminopiperidine

    CN120137930A